Status:
UNKNOWN
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy
Lead Sponsor:
Immunicon
Conditions:
Hormone Refractory Prostate Cancer
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen \[PSA\] levels) and who were about to start a new line of chemotherapy. Blood ...
Eligibility Criteria
Inclusion
- Age \> or = 18 years
- Pathological diagnosis of adenocarcinoma of the prostate
- First or later line of chemotherapy
- Serum testosterone \< 50ng/mL
- ECOG 0-2
- Serum PSA \> or = 5ng/mL
- PSA progression (2 rises above a reference value)
- Bone scan within 60 days of enrollment
- Computed tomography (CT) scan
- If measurable disease, bone scans every 6-8 months
Exclusion
- Systemic radiation
- Prior history of other carcinoma within the last 5 years, except non-melanoma skin cancer
- Brain metastases
Key Trial Info
Start Date :
December 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT00133900
Start Date
December 1 2004
End Date
February 1 2009
Last Update
July 28 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States, 44195